샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737270

전이성 암 치료제 시장

Metastatic Cancer Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 377 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전이성 암 치료제 세계 시장은 2030년까지 1,071억 달러에 달할 전망

2024년에 756억 달러로 추정되는 전이성 암 치료제 세계 시장은 2024-2030년 분석 기간 동안 CAGR 6.0%로 성장하여 2030년에는 1,071억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 화학요법제는 CAGR 7.2%를 기록하며 분석 기간 종료시에는 578억 달러에 달할 것으로 예측됩니다. 호르몬요법제 부문의 성장률은 분석 기간 동안 CAGR 4.2%로 추정됩니다.

미국 시장은 206억 달러, 중국은 CAGR 9.6%로 성장할 것으로 예측

미국의 전이성 암 치료제 시장은 2024년에 206억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 221억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.8%와 5.9%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

세계의 전이성 암 치료제 시장 - 주요 동향과 촉진요인 정리

전이성 암이 기존의 종양학 프로토콜을 넘어선 독자적인 치료 전략을 필요로 하는 이유는 무엇일까?

전이성 암은 악성 종양이 원발 부위를 넘어 원격 장기로 전이되는 단계이며, 암의 진행 중 가장 진행이 빠르고 생명을 위협하는 단계입니다. 전이성 암은 전 세계적으로 암 관련 사망의 대부분을 차지하는 가장 어려운 종양학 과제 중 하나입니다. 전이성 암은 국소 종양과 달리 복잡한 유전적 이질성을 보이고, 표준 치료에 대한 저항성을 보이며, 수술이나 방사선과 같은 국소 치료에 대한 반응성이 떨어지기 때문에 특수한 약리학적인 접근이 필요합니다.

전이성 암의 치료 목표는 완치를 목표로 하는 것에서 생존기간 연장, 삶의 질 유지, 병세 진행 억제에 중점을 두는 경우가 많습니다. 따라서 이 영역의 약물 개발은 세포 독성보다는 세포 증식 억제 효과, 전이 신호전달 경로의 표적 억제, 분자 프로파일링에 기반한 개별화에 중점을 두고 있습니다. 전이가 단순한 공간적 확대가 아닌 명확한 생물학적 상태라는 인식이 높아지면서 그 기저 메커니즘과 뇌, 뼈, 간 등 장기별 전이에 맞춘 치료법에 대한 집중적인 연구가 활발히 진행되고 있습니다.

표적 치료제, 면역종양학, 유전체기술 혁신은 어떻게 약물의 상황을 바꾸고 있는가?

전이성 암 치료법은 표적 치료제, 단클론항체, 면역관문억제제의 등장으로 극적으로 발전했습니다. 트라스투주맙(HER2+ 유방암), 오시머티닙(EGFR 변이 비소세포폐암), 엔잘루타미드(전이성 전립선암)와 같은 약물은 수용체 특이적 억제가 전이성 환경에서 어떻게 생존기간을 연장할 수 있는지를 잘 보여줍니다. 이들 약물은 비정상적인 신호전달 캐스케이드를 파괴하고, 혈관신생을 억제하거나, 호르몬 수용체를 차단하거나, 전이세포의 이동 및 접착 메커니즘을 억제하도록 설계되었습니다.

면역치료, 특히 펨브롤리주맙과 니볼루맙과 같은 PD-1/PD-L1 억제제는 종양세포의 내인성 면역 인식을 강화하여 흑색종, 비소세포폐암, 신세포암의 치료 성적에 혁명을 가져왔으며, CAR-T 세포 치료와 이중특이성 항체도 전이성 혈액종양과 고형암을 대상으로 연구되고 있습니다. 전이성 혈액종양 및 고형 종양에서 연구되고 있으며, 1차 치료를 회피하는 지속성 클론을 표적으로 삼고 있습니다. 유전체 시퀀싱 플랫폼과 액체 생검은 종양 돌연변이를 실시간으로 추적하여 환자를 정밀 치료 또는 여러 전이 촉진 인자를 동시에 표적으로 삼는 병용요법에 맞출 수 있도록 돕습니다.

전이성 종양 치료제의 임상적, 상업적 확장을 주도하는 암종과 지역 시장은?

유방암, 폐암, 대장암, 전립선암, 흑색종은 전이성 항암제 시장에서 상업적으로 가장 중요한 암종으로, 각각 상당한 환자군과 차별화된 치료 파이프라인을 보유하고 있습니다. 예를 들어, HER2 양성 유방암과 삼중음성 유방암은 전이 진행 패턴이 다르고, 그에 따른 치료법도 다릅니다. 뇌 전이를 동반한 비소세포폐암(NSCLC)은 차세대 ALK 억제제와 EGFR 억제제의 우선순위가 높은 분야입니다. 마찬가지로 전이성 대장암(mCRC)과 간세포암은 VEGF, EGFR, 멀티키나아제 경로를 표적으로 하는 생물학적 제제로 치료하는 사례가 증가하고 있습니다.

북미와 유럽은 탄탄한 상환 구조, 연구 인프라, FDA 및 EMA 승인 의약품에 대한 조기 접근성을 바탕으로 여전히 가장 큰 수익을 창출하는 지역으로 남아 있습니다. 그러나 아시아태평양 시장, 특히 중국, 일본, 한국은 암 발병률 증가, 바이오마커 기반 의료에 대한 투자, 바이오시밀러 및 국산 면역치료제의 지역 승인으로 인해 빠르게 성장하고 있습니다. 라틴아메리카와 중동은 가격 및 인프라 격차, 민관 파트너십 및 암 의료 개혁 이니셔티브를 통해 접근성을 확대하고 있습니다.

전이성 암 치료제 시장의 장기적인 성장과 혁신의 원동력은?

전이성 암 치료제 시장의 성장은 암 발병률의 증가, 분자진단 방법의 확대, 새로운 치료제의 후기 치료 알고리즘으로의 전략적 재배치 등에 의해 주도되고 있습니다. 암 면역학, 후생유전학, 종양 미세환경 조절의 획기적인 발전으로 치료 가능한 표적의 범위가 확대되고 있습니다. 동반진단 및 바이오마커를 통한 치료 선택은 환자 계층화, 반응률 향상, 후기 치료의 시행착오를 최소화할 수 있습니다.

의약품 파이프라인은 병용요법, 시퀀싱 전략, 항체약물접합체(ADC), PARP 억제제, 종양진단제 등 새로운 기전에 점점 더 초점을 맞추고 있습니다. 또한, 전이성 질환의 생명 연장 치료에 대한 지불자의 지원으로 인해 보다 광범위한 시장 진입이 가능해졌습니다. 리얼월드에비던스(RWE), 가치 기반 가격 책정 모델, 조기 승인 및 혁신 치료제 지정과 같은 규제 프레임워크는 상업화를 더욱 가속화하고 있습니다.

전이성 암 치료가 보다 개인화되고 생물학적 정보에 기반한 치료 요법으로 전환됨에 따라, 사망률이 높은 이 분야에 대한 약물 시장은 계속 확대될 것이며, 정밀 종양학, 면역조절, 중개연구의 융합이 치료 발전의 중심축으로 부상할 것입니다.

부문

치료법(화학요법, 호르몬요법, 표적요법, 면역요법), 적응증(유방암, 폐암, 전립선암, 대장암, 흑색종, 기타 적응증), 유통 채널(병원 약국, 드럭스토어·소매 약국, 온라인 프로바이더)

조사 대상 기업 사례(총 32개사)

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Seagen Inc.
  • Takeda Pharmaceutical Company

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황에서 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 최고 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Metastatic Cancer Drugs Market to Reach US$107.1 Billion by 2030

The global market for Metastatic Cancer Drugs estimated at US$75.6 Billion in the year 2024, is expected to reach US$107.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Chemotherapy Drugs, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$57.8 Billion by the end of the analysis period. Growth in the Hormonal Therapy Drugs segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.6 Billion While China is Forecast to Grow at 9.6% CAGR

The Metastatic Cancer Drugs market in the U.S. is estimated at US$20.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.1 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Metastatic Cancer Drugs Market - Key Trends & Drivers Summarized

Why Does Metastatic Cancer Demand Distinct Therapeutic Strategies Beyond Conventional Oncology Protocols?

Metastatic cancer, the stage at which malignancy spreads beyond its primary origin to distant organs, represents the most advanced and life-threatening phase of cancer progression. It remains one of the most difficult oncology challenges, accounting for the majority of cancer-related mortalities worldwide. Unlike localized tumors, metastatic cancers exhibit complex genetic heterogeneity, resistance to standard therapies, and reduced responsiveness to localized treatments like surgery and radiation-necessitating specialized pharmacologic approaches.

Treatment goals in metastatic settings often pivot from curative intent to prolonging survival, maintaining quality of life, and slowing disease progression. As such, drug development in this domain emphasizes cytostatic over cytotoxic effects, targeted inhibition of metastatic signaling pathways, and personalization based on molecular profiling. The growing recognition that metastasis represents a distinct biological state-rather than just a spatial extension-has spurred intensive research into its underlying mechanisms and therapeutics tailored for organ-specific metastases, such as brain, bone, or liver involvement.

How Are Targeted Therapies, Immuno-Oncology, and Genomic Innovations Reshaping the Drug Landscape?

The therapeutic landscape for metastatic cancer has evolved dramatically with the rise of targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors. Drugs such as trastuzumab (HER2+ breast cancer), osimertinib (EGFR-mutant NSCLC), and enzalutamide (metastatic prostate cancer) exemplify how receptor-specific inhibition can extend survival in metastatic settings. These agents are designed to disrupt aberrant signaling cascades, inhibit angiogenesis, block hormone receptors, or interfere with metastatic cell migration and adhesion mechanisms.

Immunotherapies, especially PD-1/PD-L1 inhibitors like pembrolizumab and nivolumab, are revolutionizing outcomes in melanoma, NSCLC, and renal cell carcinoma by enhancing endogenous immune recognition of tumor cells. CAR-T cell therapies and bispecific antibodies are also being explored in metastatic hematologic and solid tumors, targeting persistent clones that evade first-line treatments. Genomic sequencing platforms and liquid biopsies enable real-time tracking of tumor mutations, helping match patients to precision therapies or combination regimens that target multiple metastatic drivers simultaneously.

Which Cancer Types and Regional Markets Are Driving Clinical and Commercial Expansion of Metastatic Oncology Drugs?

Breast, lung, colorectal, prostate, and melanoma represent the most commercially significant cancer types in the metastatic drug market, each with substantial patient populations and differentiated treatment pipelines. For instance, HER2-positive and triple-negative breast cancer have distinct metastatic progression patterns and corresponding therapies. Non-small cell lung cancer (NSCLC) with brain metastases is a high-priority area for next-generation ALK and EGFR inhibitors. Similarly, metastatic colorectal cancer (mCRC) and hepatocellular carcinoma are increasingly treated with biologics targeting VEGF, EGFR, or multikinase pathways.

North America and Europe remain the largest revenue-generating regions, supported by robust reimbursement structures, research infrastructure, and early access to FDA- and EMA-approved agents. However, Asia-Pacific markets-particularly China, Japan, and South Korea-are witnessing rapid growth due to increasing cancer prevalence, investments in biomarker-driven care, and the regional approval of biosimilars and homegrown immunotherapies. Latin America and the Middle East, though constrained by pricing and infrastructure gaps, are expanding access via public-private partnerships and cancer care reform initiatives.

What Is Driving Long-Term Growth and Innovation in the Metastatic Cancer Drug Market?

The growth in the metastatic cancer drugs market is being driven by rising cancer incidence, expanded molecular diagnostics, and strategic repositioning of novel therapeutics into late-stage treatment algorithms. Breakthroughs in cancer immunology, epigenetics, and tumor microenvironment modulation are expanding the scope of druggable targets. Companion diagnostics and biomarker-guided therapy selection are enabling better stratification of patients, improving response rates and minimizing trial-and-error in late-stage treatment.

Pharmaceutical pipelines are increasingly focused on combination regimens, sequencing strategies, and novel mechanisms such as antibody-drug conjugates (ADCs), PARP inhibitors, and tumor-agnostic therapies. Additionally, payer support for life-extending therapies in metastatic settings is enabling broader market access. Real-world evidence (RWE), value-based pricing models, and regulatory frameworks like accelerated approval and breakthrough therapy designation are further accelerating commercialization.

As metastatic cancer care moves toward increasingly individualized, biologically informed treatment regimens, the market for drugs addressing this high-mortality segment will continue to expand-underscoring the convergence of precision oncology, immune modulation, and translational research as core pillars of therapeutic advancement.

SCOPE OF STUDY:

The report analyzes the Metastatic Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy); Indication (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Indications); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Seagen Inc.
  • Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Metastatic Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Late-Stage Cancer Diagnoses Drives Demand for Advanced Metastatic Cancer Therapies
    • Expansion of Immunotherapy and Targeted Therapies Throws the Spotlight on Drug Personalization
    • Rising Success of Checkpoint Inhibitors and PD-1/PD-L1 Blockers Propels New Product Pipelines
    • Development of Tumor-Agnostic Therapies Strengthens Business Case for Broad-Based Market Access
    • Increased Focus on Combination Therapies Enhances Efficacy in Resistant Metastatic Tumors
    • Growth in Companion Diagnostics and Genetic Profiling Expands Use of Precision Oncology Drugs
    • Integration of AI in Tumor Biology Research Accelerates Discovery of Novel Metastatic Pathways
    • Rapid Approvals of Orphan and Breakthrough Therapies Streamline Market Entry for High-Potential Drugs
    • Use of Liquid Biopsies for Treatment Monitoring Supports Adaptive Therapy Models
    • Collaborations Between Pharma and Diagnostic Companies Boost Development of Integrated Solutions
    • Expansion of Drug Access Programs in Low-Income Countries Strengthens Global Patient Reach
    • Clinical Trials Exploring Novel Antibody-Drug Conjugates Drive Expansion in Breast, Lung, and Colorectal Segments
    • Growth in Tumor Microenvironment Research Fuels Immunomodulatory Drug Development
    • Focus on Blood-Brain Barrier Penetration Enhances Drug Delivery for Brain Metastases
    • Use of Real-World Evidence and Digital Biomarkers Strengthens Post-Market Performance Tracking
    • Emergence of Multi-Target Inhibitors Enhances Treatment Options for Aggressive Metastatic Cancers
    • Shift Toward Value-Based Oncology Care Models Spurs Outcome-Centric Drug Pricing Strategies
    • Advancements in Nanomedicine and Smart Drug Delivery Systems Improve Target Specificity
    • Patient Advocacy and Accelerated FDA Pathways Drive Faster Commercialization of Late-Stage Therapies
    • Biopharma Investment in Pan-Cancer Drug Portfolios Expands Long-Term Strategic Market Presence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metastatic Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metastatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • JAPAN
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CHINA
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • EUROPE
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Metastatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • FRANCE
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • GERMANY
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • INDIA
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Metastatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Metastatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AFRICA
    • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제